Journal of Neuroscience · 2010 · 66 citations · 60 references
Life SciencesNeurosciencePharmacologyMolecular NeuroscienceNeuropharmacologyNeuropsychiatryAddiction NeurobiologyDopaminergic PharmacologyDopaminergic SignalingNeurochemical Signaling PathwaysNeurotransmissionStimulant TherapyAdhd TreatmentDopamine D1-like ReceptorsDopamine Receptor SignalingDopamine Receptor SubtypesDopamine TransportersKnock-in Mouse ModelsStriatal Dopamine FunctionStriatal Physiology
Attention deficit/hyperactivity disorder (ADHD) is characterized by inattention, impulsivity, and motor hyperactivity. Several lines of research support a crucial role for the dopamine transporter (DAT) gene in this psychiatric disease. Consistently, the most commonly prescribed medications in ADHD treatment are stimulant drugs, known to preferentially act on DAT. Recently, a knock-in mouse [DAT-cocaine insensitive (DAT-CI)] has been generated carrying a cocaine-insensitive DAT that is functional but with reduced dopamine uptake function. DAT-CI mutants display enhanced striatal extracellular dopamine levels and basal motor hyperactivity. Herein, we showed that DAT-CI animals present higher striatal dopamine turnover, altered basal phosphorylation state of dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP32) at Thr75 residue, but preserved D(2) receptor (D(2)R) function. However, although we demonstrated that striatal D(1) receptor (D(1)R) is physiologically responsive under basal conditions, its stimulus-induced activation strikingly resulted in paradoxical electrophysiological, behavioral, and biochemical responses. Indeed, in DAT-CI animals, (1) striatal LTP was completely disrupted, (2) R-(+)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297) treatment induced paradoxical motor calming effects, and (3) SKF 81297 administration failed to increase cAMP/protein kinase A (PKA)/DARPP32 signaling. Such biochemical alteration selectively affected dopamine D(1)Rs since haloperidol, by blocking the tonic inhibition of D(2)R, unmasked a normal activation of striatal adenosine A(2A) receptor-mediated cAMP/PKA/DARPP32 cascade in mutants. Most importantly, our studies highlighted that amphetamine, nomifensine, and bupropion, through increased striatal dopaminergic transmission, are able to revert motor hyperactivity of DAT-CI animals. Overall, our results suggest that the paradoxical motor calming effect induced by these drugs in DAT-CI mutants depends on selective aberrant phasic activation of D(1)R/cAMP/PKA/DARPP32 signaling in response to increased striatal extracellular dopamine levels.
60
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Bruno Giros, Mohamed Jaber, Sara R. Jones et al. · Nature · 1996 · 2.5K citations
Péter Klivènyi, Ole A. Andreassen, Robert J. Ferrante et al. · Journal of Neuroscience · 2000 · 1.1K citations · Full text
Characterization of Multiple Phosphorylation Sites on the AMPA Receptor GluR1 Subunit
Katherine W. Roche, Richard O’Brien, Andrew L. Mammen et al. · Neuron · 1996 · 810 citations · Full text